Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM
Prevention of relapses of Wegener's granulomatosis by treatment
with co-trimoxazole. A placebo controlled trial.
Am Soc Nephrol
J Am Soc Nephrol (abstract)
(Nov) 6:930 1995
Cotrimoxazole has been reported to benefit patients with Wegeners
granulomatosis. A multicenter, randomized, placebo-controlled study
utilizing cotrimoxazole 800/160 mg bid (equivalent to double-strength
trimethoprim/sulfamethoxazole) for 24 months in 81 patients was carried out
to determine if this drug prevented disease relapses. 8/41 patients were
unable to tolerated the drug; 7/41 drug-treated vs. 16/40 placebo-treated
patients underwent relapse during 24 mo. of followup (RR 0.40); infections
were also less frequent in the cotrimoxazole group. Prolonged treatment
with
cotrimoxazole reduces relapses and infections in patients in whom remission
has been induced with cyclophosphamide and prednisone.
(Leehey)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
Proteinuria/Hematuria :
Vasculitis (Wegener's PAN, etc.)